Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Inflammatory Bowel Disease

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Inflamm Bowel Dis.

Yao J, Jiang X, You JHS

doi: 10.1093/ibd/izaa073.

RECOMMENDED

Inflammatory Bowel Disease

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Digestion.

Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.

doi: 10.1159/000501930.

Inflammatory Bowel Disease

Relapse from deep remission after therapeutic de-escalation in inflammatory bowel disease: a systematic review and meta-analysis

J Crohns Colitis.

Zhang B, Gulati A, Alipour O, Shao L

doi: 10.1093/ecco-jcc/jjaa087.

Inflammatory Bowel Disease

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

Clin Gastroenterol Hepatol.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S

doi: 10.1016/

Inflammatory Bowel Disease

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Inflamm Bowel Dis.

Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R

doi: 10.1093/ibd/izz131.

RECOMMENDED

Inflammatory Bowel Disease

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA

doi: 10.1016/j.cgh.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

Inflammatory Bowel Disease

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Inflamm Bowel Dis.

Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ

doi: 10.1093/ibd/izaa102.

Inflammatory Bowel Disease

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease

Lancet Gastroenterol Hepatol.

Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J

doi: 10.1016/S2468-1253(19)30186-4.

Related content

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Relapse from deep remission after therapeutic de-escalation in inflammatory bowel disease: a systematic review and meta-analysis

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease